Status:
RECRUITING
Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy
Lead Sponsor:
Mansoura University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
Breast cancer patients often receive systemic drugs as the initial curative treatment of their disease. The initial systemic therapy leads to a variable degree of tumor shrinkage. At present, there is...
Detailed Description
Primary systemic (neoadjuvant) therapy (NAT) is a widely practised curative treatment for invasive breast cancer. Neoadjuvant chemotherapy (before surgery) and adjuvant chemotherapy (after surgery) ha...
Eligibility Criteria
Inclusion
- Biopsy-proven diagnosis of invasive adenocarcinoma of the breast.
- Tumor stage T 1-4b
- Nodal stage N 0-2
- ASA (American Society of Anesthesiologists) class I-II
Exclusion
- Patients opting for mastectomy.
- Patients advised for mastectomy by the treating physician.
- Patients opting for primary surgical treatment.
- Patients advised for primary surgical treatment by the treating physician.
- Metastatic patients.
- Multifocal tumors.
- Lobular neoplasia.
- Current pregnancy or pregnancy less than 6 months from the enrollment date.
- Active second cancer.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT03417622
Start Date
August 1 2019
End Date
August 1 2026
Last Update
February 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Oncology Center
Al Mansurah, DK, Egypt, 35516